期刊文献+

阿维A酸和沙利度胺对鼠黑素瘤细胞株B16增殖和VEGF表达的影响 被引量:3

Inhibitory effect of acitretin and thalidomide on proliferation and expression of VEGF in mouse melanoma cell line B16
下载PDF
导出
摘要 目的探讨阿维A酸和沙利度胺对鼠黑素瘤细胞株B16增殖的抑制作用。方法以B16细胞为研究对象,用不同浓度的阿维A酸和沙利度胺处理。(1)MTT比色法检测两药在不同的时间对B16细胞增殖的抑制作用;(2)倒置显微镜观察B16细胞形态的变化;(3)流式细胞术检测细胞周期和凋亡;(4)免疫细胞化学法测血管内皮生长因子(VEGF)的表达。结果(1)MTT法示两药对B16细胞的增殖有抑制效应。(2)倒置显微镜下可见阿维A酸组细胞不贴壁,沙利度胺组和对照组贴壁生长。(3)流式细胞术示两药处理后B16细胞G0/G1期比例增加,S期比例减少。(4)免疫细胞化学法示阿维A酸组VEGF表达受到抑制。结论两药均能抑制B16细胞增殖,抑制细胞从G0/G1期进入到S期;阿维A酸能影响B16细胞VEGF分泌,沙利度胺无此作用。 Objective To investigate the inhibitory effect of acitretin and thalidomide on proliferation of mouse melanoma B16 cells. Methods The B16 cells were treated with aeitretin and thalidomide of different concentrations. Cell inhibition was examined by MTT assay at different time point. The morphological changes of cells were observed by inverse microscopy. Flow eytometry (FCM) was used to detect apoptosis and the cell cycle. The expression of vascular endothelial growth factor (VEGF) was detected by immunoeytoehemistry. Results Aeitretin and thalidomide inhibited the proliferation of B16 cells. FCM indicated that proportion of G0/G1 was increased and S phase was decreased in aeitretin and thalidomidetreated B16 eells;apoptosis was not observed by FCM in both experimental group and control group. The expression of VEGF in the aeitretin group was lower than that in the control group. Conclusion Aeitretin and thalidomide can inhibit the proliferation of B16 cells with the increase of G0/G1 phase; while aeitretin can also inhibit the expression of VEGF.
出处 《实用肿瘤杂志》 CAS 2007年第6期495-498,共4页 Journal of Practical Oncology
关键词 黑素瘤/药物作用 黑素瘤/病理学 肿瘤细胞 培养的 沙利度胺/药理学 血管内皮生长因子A 细胞凋亡 阿维A/药理学 melanoma/drug effects melanoma/pathology tumor cells,cultured thalidomide/pharmacology vascular endothelial growth factor A apoptosis acitretin/pharmacology
  • 相关文献

参考文献11

二级参考文献47

  • 1[1]Slodkowska J, Sikora J, Roszkowski-Sliz K, et al. Expression of vascular endothelial growth factor and basic fibroblast growth factor receptors in lung cancer. Anal Quant Cytol Histol, 2000, 22: 398~402.
  • 2[2]Kebel RS. Tumor angiogenesis: past, present and the near fu ture. Carcinogenesis, 2000, 21(3): 505~15.
  • 3[3]D' Amato RJ, Loughman MS, Flynn E.Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA, 1994, 91: 4082~5.
  • 4[4]Folkman J.Tumor angiogenesis: Therapeutic implications. N Engl J Med, 1971, 285: 1182~6.
  • 5[5]Minchinton AI, Fryer KH, Wendt KR, et al. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs, 1996, 7: 339~43.
  • 6[6]Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and tis analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 2000, 96: 2943~ 50.
  • 7[7]Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple mye1oma. Mayo Clin Proc, 2000, 89: 488~ 99.
  • 8[8]Singhal S, Mehta J, Desikan R, et al.Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 2000, 342: 344.
  • 9[9]Shimazawa R, Miyachi H, Takayama H, et al.Antiangiogenic activity of tumor necrosis factor-α production regulators derived from thalidomide. Biol Phar Bull, 1999, 22(2) :224~6.
  • 10[10]Fine HA, Figg WD, Jaeckle K, et al. Phase trial of the an tiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol, 2000, 18: 708~15.

共引文献249

同被引文献43

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部